News

Results from the SUMMIT basket study revealed encouraging results with the triplet regimen in patients with HR-positive/HER2-negative MBC compared with other variations and monotherapies of the 3 drugs.

The addition of brentuximab vedotin to standard chemotherapy achieved a 41% reduction in the risk of death in patients with advanced-stage Hodgkin lymphoma in the ECHELON-1 study.

In an interview with Targeted Oncology, Mary O’Brien, MD, discussed background of the second interim analysis of the triple-blind, phase 3 PEARLS/KEYNOTE-091 study.

Results from a phase 2 study show poziotinib demonstrates significant antitumor activity for patients with EGFR exon 20 positive non–small cell lung cancer.

The development of vicineum for the treatment of patients with high-risk, Bacillus Calmette-Guerin-unresponsive non–muscle invasive bladder cancer has been voluntarily paused.

Adam Weiner, MD, discusses the importance of molecular testing for prostate cancer and what the current targeted therapy landscape looks like for this disease.

The phase 3 ZILO-301 study will evaluate the combination of zilovertamab and ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

There are several trials with oral SERDs in clinical development for hormone-receptor-positive metastatic breast cancer as both monotherapies and in combination therapy.

In an interview with Targeted Oncology, Lajos Pusztai, MD, DPhil, discussed the updated findings of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in patients with TNBC vs placebo plus chemotherapy.

Investigators at Tulane University have identified a relationship that linked cancer incidence and cancer risk from air pollution in Louisiana among Black or low-income communities, which were more likely to be affected than other populations.

An orphan drug designation has been granted to DSP-0390 by the FDA as treatment in patients with brain cancer.

The Pediatric Oncology Subcommittee of the FDA’s Oncologic Drug Advisory Committee met to discuss the assessment of new drugs for the treatment of pediatric cancers. The goal of the meeting was to develop a new framework for application review.

Gabriela Hobbs, MD, discusses the unmet needs that have yet to be filled in the post-myeloproliferative neoplasm acute leukemia space.

Siddhartha Mukherjee, MD, explains the current golden standard for frontline treatment of patients with acute myeloid leukemia.

Findings from the phase 3 APHINITY study show that the combination pertuzumab, trastuzumab, and chemotherapy improves invasive disease-free survival compared with trastuzumab and chemotherapy alone in patients with lymph node-positive, HER2-positive early breast cancer.

In an interview with Targeted Oncology, Cristian Tomasetti, PhD, discussed the role of circulating tumor DNA in understanding the need for adjuvant chemotherapy in patients with stage II colon cancer. He explained how circulating tumor DNA can signal a patient’s risk of disease recurrence after surgery.

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed phase 3 MOMENTUM study and how it has impacted the clinical trial development of momelotinib for the treatment of patients with myelofibrosis.

The FDA has approved crizotinib as treatment for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory ALK-positive myofibroblastic tumors.

A highly anticipated presentation at the 2022 World Conference on Lung Cancer will be the first report of efficacy and safety from the phase 1b/2 CodeBreak 101 clinical trial and will provide updated results from the phase 2 CodeBreak 100 study.

Ryan Sugarman, MD, discusses the key takeaways from the CheckMate-649 trial of patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receiving nivolumab combined with chemotherapy compared with chemotherapy alone in the first-line.

The FDA has deferred action on the biologics license application for tislelizumab as a second-line treatment in esophageal squamous cell carcinoma.

Upcoming data from part C of the DisTinGuish study will further confirm the benefit and safety of DKN-01 in combination with tislelizumab in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.

In the interview, Mark Markowski, MD, discussed how the findings from the phase 1/2 trial of sabizabulin in patients with metastatic castration-resistant prostate cancer this may influence future research with the oral agent.

Visits to the phase 3 FLAMINGO-01 clinical trial sites have been initiated following the lift of a FDA clinical hold.

Orphan drug designation has been granted to NT-I7 by the FDA for patients with glioblastoma multiforme.

Results from the primary analysis of the phase 3 COSMIC-313 trial showed significant improvement in progression-free survival in patients with renal cell carcinoma receiving the combination of cabozantinib, nivolumab, and ipilimumab.

An orphan drug designation and a fast track designation have been granted by the FDA to a novel sonodynamic therapy platform as a potential treatment for patients with recurrent glioblastoma and other malignant gliomas.

In an interview with Targeted Oncology, Matthew T. Campbell, MD, examined the positive phase 1 study results of infigratinib for the treatment of patients with localized upper tract urothelial cancer.

Hispanic and Black men are showing higher cancer-specific mortality rates from HPV-associated throat cancer, and most new cases are being diagnosed in White men at a late-stage.

Remote technology and decentralization tools in cancer clinical trials may be linked to an increase in patient consent rate, according to findings from a cross-sectional study.